This report focuses on the U.S. Food and Drug Administration (FDA) as a key player in federal efforts to curb the opioid epidemic. It provides an overview of FDA's role in approving new prescription drugs, including challenges of approval and regulation of opioid products; addresses FDA's multifaceted approach in responding, including recent agency action; and concludes with a discussion of selected opioid-related legislation in the 115th Congress.
Serving as both a federal and a state depository library, the UNT Libraries Government Documents Department maintains millions of items in a variety of formats. The department is a member of the FDLP Content Partnerships Program and an Affiliated Archive of the National Archives.
This report focuses on the U.S. Food and Drug Administration (FDA) as a key player in federal efforts to curb the opioid epidemic. It provides an overview of FDA's role in approving new prescription drugs, including challenges of approval and regulation of opioid products; addresses FDA's multifaceted approach in responding, including recent agency action; and concludes with a discussion of selected opioid-related legislation in the 115th Congress.
This report is part of the following collection of related materials.
Congressional Research Service Reports
The Congressional Research Service (CRS) is the public policy research arm of Congress. This legislative branch agency works exclusively for Members of Congress, their committees and their staff. This collection includes CRS reports from the mid-1960's through 2018—covering a variety of topics from agriculture to foreign policy to welfare.
Staman, Jennifer A.The Opioid Epidemic and the Food and Drug Administration: Legal Authorities and Recent Agency Action,
report,
June 5, 2018;
Washington D.C..
(https://digital.library.unt.edu/ark:/67531/metadc1213112/:
accessed May 14, 2024),
University of North Texas Libraries, UNT Digital Library, https://digital.library.unt.edu;
crediting UNT Libraries Government Documents Department.